Eupraxia Pharmaceuticals (EPRX) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical milestones in 2025, including positive data from the RESOLVE trial for EP-104GI in eosinophilic esophagitis and strengthened financial position through two financings.

• Anticipates multiple clinical readouts and initiation of new clinical programs in 2026 to expand the pipeline.

Financial highlights

• Reported net loss of $16.7 million for Q4 2025, compared to $7.5 million in Q4 2024, mainly due to increased R&D and administrative costs.

• Cash balance was $80.5 million as of December 31, 2025, up from $33.1 million at the end of Q4 2024.

• Raised approximately $63.2 million in gross proceeds from a public offering in February 2026.

Outlook and guidance

• Existing cash reserves, proceeds from the offering, and anticipated warrant exercises are expected to fund operations into the second half of 2028.

• Expects continued access to U.S.-manufactured clinical supplies despite ongoing tariff uncertainties.

• Plans for multiple clinical readouts and new program initiations in 2026.